New hope for genital eczema: drug trial targets severe itch and pain
NCT ID NCT07444801
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether tralokinumab, an approved eczema drug, can improve moderate-to-severe atopic dermatitis in the genital area. About 30 adults will receive the drug and be monitored for 52 weeks using special skin imaging and symptom questionnaires. The goal is to see if it reduces itching, redness, and discomfort in this sensitive region.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (MODERATE-TO-SEVERE) INVOLVING THE GENITAL REGION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CCIM, Institut für Entzündungsmedizin UKSH Lübeck
RECRUITINGLübeck, Schleswig-Holstein, 23538, Germany
-
Department of Dermatology of the University Hospital Augsburg
RECRUITINGAugsburg, München, 86156, Germany
Contact Email: •••••@•••••